Lido Advisors LLC Takes Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Lido Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 27,487 shares of the company's stock, valued at approximately $364,000.

Several other hedge funds have also recently made changes to their positions in TAK. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB purchased a new stake in Takeda Pharmaceutical during the third quarter valued at approximately $40,000. Farther Finance Advisors LLC increased its holdings in Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after buying an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. purchased a new stake in Takeda Pharmaceutical during the fourth quarter valued at approximately $52,000. Finally, Cromwell Holdings LLC purchased a new stake in Takeda Pharmaceutical during the fourth quarter valued at approximately $61,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

TAK stock traded up $0.09 during midday trading on Friday, reaching $14.36. 4,353,385 shares of the company's stock traded hands, compared to its average volume of 1,889,107. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.43. The stock has a market cap of $45.69 billion, a P/E ratio of 35.90, a PEG ratio of 0.24 and a beta of 0.26. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average is $14.87 and its 200 day moving average is $14.00.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.